Published On: Wed, Jul 8th, 2015

Biopharma co Chiasma updates Nasdaq IPO terms

The company will raise $80 million to build a marketing network for its oral acromegaly treatment.

Chiasma-Roni Mamluk

 

Biopharmaceutical company Chiasma has updated the terms of its Nasdaq IPO with the US Securities and Exchange Commission (SEC). The company, which recently submitted a request for marketing approval of its drug for treatment of acromegaly, a diseas stemming from excessive hormone growth, will raise $80 million, and up to $92 million if the underwriters options are realized. Barclays Capital and Cowen & Co. are leading the offering with William Blair and Oppenheimer as the secondary underwriters… READ MORE

 

GLOBES logo-eng (1) Published by Globes [online], Israel business news – www.globes-online.com

 

READ MORE:

Chiasma Raises $70 Million to Advance Its Endocrine Disease Medication

Israeli-American privately held biomed company Chiasma announced the closing of a $70 million Series E financing round. The company will use the new capital to build its sales and marketing capabilities and prepare More…

Oral Meds

Gil Tanenbaum On Saturday, January 3rd, 2015

Israeli-American Biomed Firm Chiasma Raises $33.8 Million to Continue Development of Oral Meds

Israeli biomed company Chiasma has raised $33.8 million out of a planned total $56.3 million round of fundraising. It plans to use the infusion of new capital to continue the development of its oral octreotide. MPM More…

ROCHE-300x155

Gali Weinreb On Wednesday, August 6th, 2014

Roche Cancels $600 Million Chiasma Deal

Chiasma: The product is good. This was a strategic decision by Roche to be less involved in hormone-based drugs. – Roche AG (SWX: ROG) has notified Israeli startup Chiasma that it has cancelled a commercial More…

Read more about: , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems